Gene Editing Companies Have Long-Term Potential to Be M&A Targets

Healthcare >> Analyst Interviews >> March 16, 2018

Gbola Amusa is Partner, Director of Research and Head of Healthcare Research of Chardan. Dr. Gbola Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns by creating shared value for society. Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma and Biotech Coordinator at UBS, where he oversaw 25 analysts and ultimately finished as the number-one-ranked European pharma analyst in the Institutional Investor — II — Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a health care finance and strategy consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa’s views on health care have been cited by socially responsible investing, or SRI; ESG; and sustainability organizations like FSG/Shares Value Initiative, GMI Ratings and the ATM Index. Dr. Amusa earned his BSE from Duke University, an M.D. at Washington University Medical School and his MBA from the University of Chicago Booth School of Business. Profile

TWST: Given that you have particular insights with your background in medicine, how does gene editing and gene therapy fit in the broader context of biotech as an investment

Join for free to read a longer excerpt or purchase this article
Already a member? Login here

Gene Editing Companies Have Long-Term Potential to Be M&A Targets

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Gene Editing Companies Have Long-Term Potential to Be M&A Targets

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS